US Dollar vs Yen

登録してリアルタイムのアラート、カスタムポートフォリオ、市場の動きを入手してください。

ホーム
投資
株式
オーストラリア
ASX
Sarytogan Graphite Ltd (SGAO) 銘柄情報

Sarytogan Graphite Ltd (SGAO)

0.01

0.00

(0.00%)

終了 7月4日 3:00PM

Sarytogan Graphite Ltd (SGAO) 銘柄情報

リアルタイムのディスカッションと取引のアイデア: 当社の強力なプラットフォームで自信を持って取引できます。

プレミアム

通貨

0.01

( - )

買値

0.01

売値

0.013

出来高

0.00

0.00 日の範囲 0.00

0.01 52 週間の範囲 0.026

時価総額

前日終値

0.01

始値

-

時刻

最終取引時間

財務取引量

-

VWAP

-

平均取引量 (3 か月)

AUD 156,639

発行済株式数

264,330,600

配当利回り

PER

-4.39

1 株当たり利益 (EPS)

-0.01

歳入

-

純利益

-2.67M

Sarytogan Graphite Limited engages in the exploration of graphite properties. The company holds 100% interest in the Sarytogan Graphite project located in the Karaganda region of Central Kazakhstan. It also owns interest in the Baynazar Copper project located in Central Kazakhstan; and Kopa Copper P... Sarytogan Graphite Limited engages in the exploration of graphite properties. The company holds 100% interest in the Sarytogan Graphite project located in the Karaganda region of Central Kazakhstan. It also owns interest in the Baynazar Copper project located in Central Kazakhstan; and Kopa Copper Project located in South Kazakhstan. Graphite Limited was incorporated in 2004 and is based in Subiaco, Australia. 詳細を表示

セクター

Materials

業界

Mining

ウェブサイト

www.sarytogangraphite.com.au

本社

Subiaco, Australia

設立

2026

Sarytogan Graphite Ltd is listed in the Materials sector of the オーストラリア証券取引所 with ticker SGAO. The last closing price for Sarytogan Graphite was AUD0.01. Over the last year, Sarytogan Graphite shares have traded in a share price range of AUD 0.01 to AUD 0.026.

Sarytogan Graphite currently has 264,330,600 shares in issue. The market capitalisation of Sarytogan Graphite is AUD2.64 million. Sarytogan Graphite has a price to earnings ratio (PE ratio) of -4.39.

表示するニュースはありません。

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	0	0	0	0	0	0	0	DE
4	-0.001	-9.09090909091	0.011	0.011	0.01	146389	0.01005123	DE
12	-0.008	-44.4444444444	0.018	0.018	0.01	235476	0.01247792	DE
26	-0.013	-56.5217391304	0.023	0.026	0.01	144784	0.01550967	DE
52	-0.007	-41.1764705882	0.017	0.026	0.01	173854	0.01803727	DE
156	-0.072	-87.8048780488	0.082	0.125	0.001	123237	0.03102321	DE
260	-0.055	-84.6153846154	0.065	0.28	0.001	167596	0.11435514	DE

SGAO - Frequently Asked Questions (FAQ)

What is the current Sarytogan Graphite Ltd share price?

The current share price of Sarytogan Graphite Ltd is AUD 0.01

How many Sarytogan Graphite Ltd shares are in issue?

Sarytogan Graphite Ltd has 264,330,600 shares in issue

What is the market cap of Sarytogan Graphite Ltd?

The market capitalisation of Sarytogan Graphite Ltd is AUD 2.64M

What is the 1 year trading range for Sarytogan Graphite Ltd share price?

Sarytogan Graphite Ltd has traded in the range of AUD 0.01 to AUD 0.026 during the past year

What is the PE ratio of Sarytogan Graphite Ltd?

The price to earnings ratio of Sarytogan Graphite Ltd is -4.39

What is the registered address of Sarytogan Graphite Ltd?

The registered address for Sarytogan Graphite Ltd is 110 Hay Street, Subiaco, Western Australia, 6000

What is the Sarytogan Graphite Ltd website address?

The website address for Sarytogan Graphite Ltd is www.sarytogangraphite.com.au

Which industry sector does Sarytogan Graphite Ltd operate in?

Sarytogan Graphite Ltd operates in the Mining sector

williamssc

williamssc 3分前

Slide16 “Overall Conclusions: The survival benefit associated with DCVax-L treatment reflects a true treatment affect and was underestimated in the original analysis”

NASDAQ2020

NASDAQ2020 4分前

i will wait for Monday to grab some more ??

GoodGuyBill

GoodGuyBill 5分前

Brazen22, you’re trying to reduce three years of regulatory progress to one sentence: “You don’t have an approved MAA.”

Of course we don’t — yet. Approval is the destination. We have a validated MAA. What matters is whether NWBO has completed the steps that regulators require before a

NASDAQ2020

NASDAQ2020 5分前

THATS WHEN i ACCUMULATE. At The hammerbottom.

nowwhat2

nowwhat2 5分前

https://investorshub.advfn.com/uimage/uploads/2026/7/3/vwgethg_july_3_2y_plunge_sell.jpg

rizona

Slides! JAMA study UNDERESTIMATED survival benefit

https://nwbio.com/wp-content/uploads/NWBT-BNOS-slides-7-3-26MB-LP-final.pdf

rosemountbomber

rosemountbomber 7分前

I agree with your thinking and also what needs to be considered is after decimating the board, just a desire to be acquired doesn’t automatically make that happen. Some other party has to be interested in acquiring Amarin. What happens then if no one steps up?

chereb19

chereb19 8分前

This is another post built on false equivalence. Sharing Y-90 doesn't make two products the same any more than sharing aspirin makes every painkiller identical.

You keep calling them competitors while ignoring they're fundamentally different technologies. One is a hydrogel platform, t

NASDAQ2020

NASDAQ2020 9分前

Im glad I held my shares past $0.15

Idunno

Idunno 10分前

And don’t forget your buddy, AF. … .. .

Doc logic

Doc logic 10分前

HappyLibrarian,

You are mistakenly overstating my claim which is a common problem so no harm no foul. Manufacturing transition preparedness is what I am suggesting must be in place. Artisan will be utilized to start as NWBO has consistently stated and the MIA is based on that model.

rcaselli

rcaselli 10分前

Just knowing JCTB1 is here is good enuf for me, okay.
See ya all topside….
$LBRG

Idunno

Idunno 10分前

Have at it Brazen! ;) … .. . :)

CatfishHunter

CatfishHunter 13分前

Every biotech founder believes their design choice was the right one — that’s true of BetaGlue’s surgeon-founder and it was true of Fisher/Korenko too. Design rationale explains intent, not outcome. The question that matters is what the trial data shows for each product, not why either team picked t

asp42001

asp42001 13分前

Digital USIO & AI Payment Potential:

(USIO In-Part):

"Embedded payments are the hidden engine under the hood of the apps and platforms we use every day. When you buy a ticket through a sports app or pay for a round of golf lessons online, embedded payments are doing the

BigBadWolf

BigBadWolf 13分前

$Ownership😘 of @ this point w/ irrefutable DD
🤔https://investorshub.advfn.com/boards/read_msg.aspx?message_id=177573771&txt2find=reactor

mgland

mgland 14分前

https://x.com/thommic/status/2072760144774005081

GTF

Just so you know the clock on the 12 month restricted period for SNTX divvy shares began on June 17th, 2026. It doesn't matter that the deliverance of shares to the gtvh shareholders is taking some time. The clock begins when SNTX creates and issues the shares...meaning the day OTCmarkets shows the

manibiotech

manibiotech 17分前

I like this line in couple of PSM analysis slides:

“ Conclusion: Based on these more precisely matched comparisons,
the survival benefit with DCVax-L was likely underestimated
in the original analysis”

Very encouraging . Now let’s see when MHRA does its jo

ErnieBilco

ErnieBilco 17分前

Good to know because I was thinking about letting it go but now I have a reason to hold

gdog

This is by far the Best piece Gary has written imho

https://garywallach.substack.com/p/from-qualification-to-harvest-could?r=3iu9hl&utm_campaign=post&utm_medium=web&triedRedirect=true

AngeloFoca

AngeloFoca 18分前

I doubt you will agree or bother reading what I have said but at least it wasn’t written by some AI.
I have read it all and you are right... I don't agree with ANY of it.

No, I don't believe they have done EVERYTHING right... But I do believe that had it been any other CEO...

rmoss

Stay away stay very far away........

flipper44

flipper44 21分前

I’m busy today, but these results are in line with what I expected. Excellent, and very helpful for all current and potential stakeholders. Great for patients! For current therapy as well as future improvements with combination therapy. Happy 4th Tomorrow! (Top notch for valuation)

stoxjock

stoxjock 21分前

Ok, This Explains it. I didn't know which Wall St (Or elsewhere in Europe like James St) Scoundrel "Creditors' were "Filing TWICE or even More' to get their Money from multiple Lehman Entities ..Frankly, those SCUM should be prosecuted for Fraud and Thrown in Jail for Good...

Sarytogan Graphite

Podium Minerals

Professional Diversity N...

Sleeping Giant Capital

Euronext Eurozone ESG La...

Eastern Resources

Integrated Research

Perpetual Resources

Harvest Healthcare Leade...

Delayed Upgrade Clock

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約

ADVFN

すでにアカウントをお持ちですか？サインイン

アカウントをお持ちでないですか？登録

登録することで、ADVFN の利用規約を読み、理解し、同意したこと、および私が個人投資家であることを確認します。